Hims & Hers Health, Inc. $HIMS Shares Sold by Proem Advisors LLC

Posted by Geri Gentry on May 12th, 2026

Proem Advisors LLC cut its stake in Hims & Hers Health, Inc. (NYSE:HIMS – Free Report) by 47.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 45,000 shares of the company’s stock after selling 40,000 shares during the quarter. Hims & Hers Health comprises approximately 0.2% of Proem Advisors LLC’s investment portfolio, making the stock its 27th biggest position. Proem Advisors LLC’s holdings in Hims & Hers Health were worth $1,461,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of HIMS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Hims & Hers Health by 23.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock worth $12,373,000 after acquiring an additional 78,543 shares during the last quarter. Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health in the 1st quarter worth $30,000. EverSource Wealth Advisors LLC increased its stake in shares of Hims & Hers Health by 273.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock worth $47,000 after acquiring an additional 687 shares during the last quarter. Amundi increased its stake in shares of Hims & Hers Health by 5.3% in the 2nd quarter. Amundi now owns 10,296 shares of the company’s stock worth $489,000 after acquiring an additional 522 shares during the last quarter. Finally, California Public Employees Retirement System increased its stake in shares of Hims & Hers Health by 9.5% in the 2nd quarter. California Public Employees Retirement System now owns 338,620 shares of the company’s stock worth $16,880,000 after acquiring an additional 29,471 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

Positive Sentiment: Management raised full-year 2026 revenue guidance to $2.8 billion-$3.0 billion, above Wall Street estimates, and also guided Q2 revenue to $680 million-$700 million, topping consensus. This suggests the company expects growth to reaccelerate after a soft Q1. Hims & Hers Health (NYSE:HIMS) Misses Q1 CY2026 Sales Expectations, Stock Drops 11.5%
Positive Sentiment: Hims & Hers is expanding its digital healthcare platform with new offerings including Labs, menopause care, testosterone care, global acquisitions, and a Novo Nordisk GLP-1 partnership, which could broaden its addressable market over time. Hims & Hers Expands Digital Healthcare Platform via New Care Offerings
Positive Sentiment: Some analysts argue the mixed quarter does not break the long-term investment thesis, pointing to a potential bottoming process and a strategic shift away from compounded GLP-1s toward branded partnerships that may reduce legal and regulatory risk. Hims & Hers Health: Mixed Q1 2026 Is Not A Thesis Breaker
Neutral Sentiment: The company reported first-quarter 2026 revenue of $608.1 million, up about 4% year over year but below estimates, and said it will move from quarterly shareholder letters to an annual letter while continuing regular earnings releases and calls. Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Results
Negative Sentiment: Q1 results were disappointing, with adjusted and GAAP losses wider than expected and revenue missing consensus, while expenses rose and margins compressed, which is the main reason the stock sold off after the report. Hims & Hers Health Swings to First-Quarter Loss as Expenses Rise

Insiders Place Their Bets

In related news, COO Michael Chi sold 97,289 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $2,402,065.41. Following the completion of the transaction, the chief operating officer directly owned 407,282 shares in the company, valued at $10,055,792.58. This trade represents a 19.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Soleil Boughton sold 9,463 shares of the firm’s stock in a transaction dated Monday, April 20th. The shares were sold at an average price of $30.00, for a total value of $283,890.00. Following the transaction, the insider owned 299,368 shares of the company’s stock, valued at $8,981,040. This trade represents a 3.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 204,857 shares of company stock valued at $5,285,706 over the last 90 days. Company insiders own 13.71% of the company’s stock.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of recent research reports. Morgan Stanley cut their target price on Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 24th. Bank of America raised their price objective on Hims & Hers Health from $30.00 to $32.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday. Citigroup raised Hims & Hers Health from a “sell” rating to a “neutral” rating and raised their price objective for the stock from $13.25 to $24.00 in a research report on Tuesday, March 10th. Finally, Evercore set a $24.00 price objective on Hims & Hers Health in a research report on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $31.86.

Read Our Latest Research Report on HIMS

Hims & Hers Health Stock Up 3.0%

Shares of NYSE:HIMS opened at $29.12 on Tuesday. The business has a 50-day moving average price of $23.08 and a 200 day moving average price of $29.44. The company has a current ratio of 1.90, a quick ratio of 1.70 and a debt-to-equity ratio of 1.80. The company has a market capitalization of $6.64 billion, a price-to-earnings ratio of 57.10, a PEG ratio of 3.85 and a beta of 2.43. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $70.43.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The business had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The firm’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.20 earnings per share. Sell-side analysts expect that Hims & Hers Health, Inc. will post 0.53 EPS for the current year.

Hims & Hers Health Profile

(Free Report)

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.